Brief: Fennec Updates NCCN Clinical Practice Guidelines, Recommend PEDMARK
25/01/2023 13:13
Jan 25 (Reuters) - Fennec Pharmaceuticals Inc FENC.O :
* FENNEC PHARMACEUTICALS ANNOUNCES UPDATED NCCN CLINICAL
PRACTICE
GUIDELINES RECOMMEND PEDMARK® (SODIUM THIOSULFATE INJECTION) TO
REDUCE THE RISK OF CISPLATIN-INDUCED HEARING LOSS IN PEDIATRIC
PATIENTS
Source text for Eikon: ID:nGNX3jQl2l
Further company coverage: FENC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fennec Pharmaceuticals
See all newsFennec Pharmaceuticals Inc. reports results for the quarter ended June 30 - Earnings Summary
Fennec Pharmaceuticals Q2 sales rise on PEDMARK demand
Fennec Pharmaceuticals Inc. expected to post earnings of 1 cent a share - Earnings Preview
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple